공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 환자유래이종이식(PDX) 모델 시장 예측(-2026년) : 유형(마우스, 래트), 종양 유형(위장, 부인과, 혈액), 용도(전임상 의약품 개발, 바이오마커 분석), 최종사용자(제약, 바이오테크놀러지, CRO), 지역별

Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026

리서치사 MarketsandMarkets
발행일 2021년 04월 상품 코드 1001813
페이지 정보 영문 171 Pages
가격
US $ 4,950 ₩ 5,680,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,650 ₩ 7,630,000 PDF (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,150 ₩ 9,352,000 PDF (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없지만, 동일 국가의 동일 사업장에 한정되며 해외지점 등은 포함되지 않습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,000 ₩ 11,475,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 환자유래이종이식(PDX) 모델 시장 예측(-2026년) : 유형(마우스, 래트), 종양 유형(위장, 부인과, 혈액), 용도(전임상 의약품 개발, 바이오마커 분석), 최종사용자(제약, 바이오테크놀러지, CRO), 지역별 Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026
발행일 : 2021년 04월 페이지 정보 : 영문 171 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 환자유래이종이식(PDX) 모델 시장 규모는 예측 기간 중 16.4%의 CAGR로 추이하며, 2021년 1억 4000만 달러에서 2026년에는 2억 9900만 달러 규모로 성장할 것으로 예측됩니다.

맞춤형 의료에 대한 수요의 증가, 암연구에 대한 지속적 지원, 제약회사에 의한 R&D의 확대 등의 요인이 이 시장의 성장을 촉진하고 있습니다. 또한 인간화 PDX 모델에 대한 수요의 증가가 성장의 기회를 보일 것으로 기대되고 있습니다. 한편, 개별화 PDX 모델의 고비용성, 암연구에서 동물 실험의 윤리성에 관한 엄격한 가이드라인, PDX 모델에 부수하는 각종 제약 등이 예측 기간 중 시장 성장을 일정 정도 억제할 것으로 예측됩니다.

세계의 환자유래이종이식(PDX) 모델 시장을 조사했으며, 시장의 정의와 개요, 밸류체인, 신종 코로나바이러스 감염증(COVID-19) 및 기타 시장 영향요인 분석, 법규제 환경, 기술·특허 동향, 시장 규모의 추이·예측, 유형·종양 유형·용도·최종사용자·지역/주요 국가별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

제1장 서론

제2장 조사 방법

제3장 개요

제4장 중요 인사이트

제5장 시장 개요

  • 시장 역학
    • 촉진요인
    • 억제요인
    • 시장 기회
    • 과제
  • COVID-19의 영향
  • 기술 분석
  • 가격 분석
  • 밸류체인 분석
  • PDX 에코시스템 분석
  • Porter의 산업 분석
  • 규제 분석
  • 특허 분석

제6장 시장 분석·예측 : 유형별

  • 마우스 모델
  • 래트 모델

제7장 시장 분석·예측 : 종양 유형별

  • 소화관 종양 모델
  • 부인과 종양 모델
  • 호흡기 종양 모델
  • 비뇨기 종양 모델
  • 혈액 종양 모델
  • 기타

제8장 시장 분석·예측 : 용도별

  • 전임상 의약품 개발
  • 바이오마커 분석
  • 암의 기초 조사

제9장 시장 분석·예측 : 최종사용자별

  • 제약·바이오테크놀러지 기업
  • CRO
  • 학술연구기관

제10장 시장 분석·예측 : 지역·주요 국가별

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 기타
  • 아시아태평양
    • 중국
    • 일본
    • 기타
  • 라틴아메리카
  • 중동·아프리카

제11장 경쟁 구도

  • 개요
  • 시장 평가 프레임워크
  • 시장 점유율 분석
  • TOP 기업의 매출 점유율 분석
  • 기업 평가 쿼드런트
  • 기업 평가 쿼드런트 : 신규 기업/중소기업
  • 기업의 제품 발자국
  • 기업의 지역적 발자국
  • 경쟁 시나리오

제12장 기업 개요

  • 주요 기업
    • JSR CORPORATION
    • WUXI APPTEC
    • THE JACKSON LABORATORY
    • CHARLES RIVER LABORATORIES
    • CHAMPIONS ONCOLOGY
    • ONCODESIGN
    • ENVIGO
    • PHARMATEST SERVICES
    • HERA BIOLABS
    • EPO BERLIN-BUCH GMBH
    • XENTECH
    • UROSPHERE
  • 기타 기업
    • ABNOVA CORPORATION
    • GENESIS BIOTECHNOLOGY GROUP
    • EXPLORA BIOLABS
    • BIOCYTOGEN
    • LIVING TUMOR LABORATORY
    • BIODURO
    • ARAGEN LIFE SCIENCES W.E.F
    • SHANGHAI LIDE BIOTECH

제13장 부록

KSA 21.05.03

The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4% during the forecast period. Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market. However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.

"The preclinical drug development segment accounted for the highest growth rate in the PDX models market, by application, during the forecast period"

The PDX models market is segmented into preclinical drug development, biomarker analysis, and basic cancer research. The preclinical drug development segment accounted for the highest growth rate in the PDX models market during the forecast period. This segment's high growth rate can be attributed to the rising number of clinical trials every year.

"Contract research organizations segment accounted for the highest CAGR"

Based on end users, the PDX models market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. During the forecast period contract research organizations accounted for the highest growth rate. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.

"Rat models segment accounted for the highest CAGR"

Based on type, the PDX models market is segmented into mice models and rat models. The rat models segment accounted for the highest growth rate during the forecast period. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. Moreover, the development of immunodeficient rats will further drive the usage of rat models in PDX model generation.

"Respiratory tumor models segment accounted for the highest CAGR"

Based on tumor type, the PDX models market is segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models. The respiratory tumor models segment accounted for the highest growth rate during the forecast period. The key factor driving this segment's growth is the increasing incidence of lung cancers globally.

"Asia Pacific: The fastest-growing country in the PDX models market"

The PDX models market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the PDX models market in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70%, and Demand Side - 30%
  • By Designation (Supply Side): Managers - 45%, CXOs and Directors - 30%, and Executives- 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

Lists of Companies Profiled in the Report:

  • JSR Corporation (Japan)
  • WuXi AppTec (China)
  • Champions Oncology, Inc. (US)
  • THE JACKSON LABORATORY (US)
  • Charles River Laboratories (US)
  • Oncodesign (France)
  • Envigo (US)
  • Pharmatest Services (Finland)
  • Hera BioLabs (US)
  • EPO Berlin-Buch GmbH (Germany)
  • Xentech (France)
  • Urosphere (France)
  • Abnova Corporation (Taiwan)
  • Genesis Biotechnology Group (US)
  • Explora BioLabs (US)
  • Biocytogen (US)
  • Living Tumor Laboratory (Canada)
  • Bioduro (US)
  • Aragen Life Sciences w.e.f, (US)
  • Shanghai Lide Biotech Co., Ltd. (China)

Research Coverage:

This report provides a detailed picture of the PDX models market. It aims at estimating the size and future growth potential of the market across different segments, such as type, tumor type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall PDX models market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED IN THE REPORT
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
    • FIGURE 3 PDX MODELS MARKET: BREAKDOWN OF PRIMARIES
      • 2.1.2.1 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 - REVENUE SHARE ANALYSIS, 2020
    • FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020
    • FIGURE 6 PDX MODELS MARKET: CAGR PROJECTIONS, 2021-2026
    • FIGURE 7 PDX MODELS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 9 PDX MODELS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 10 PDX MODELS MARKET, BY TUMOR TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 11 PDX MODELS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 12 PDX MODELS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 PDX MODELS MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 PDX MODELS MARKET OVERVIEW
    • FIGURE 14 INCREASING SUPPORT FOR CANCER RESEARCH FROM PUBLIC AND PRIVATE SECTORS AND GROWING DEMAND FOR PRECISION MEDICINE ARE KEY GROWTH DRIVERS
  • 4.2 NORTH AMERICA: PDX MODELS MARKET, MARKET SHARE (2020)
    • FIGURE 15 MICE MODELS COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN PDX MODELS MARKET IN 2020
  • 4.3 PDX MODELS MARKET SHARE, BY END USER (2020)
    • FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED THE LARGEST SHARE OF THE PDX MODELS MARKET IN 2020
  • 4.4 PDX MODELS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 17 CHINA TO WITNESS THE HIGHEST GROWTH IN THE PDX MODELS MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 PDX MODELS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 1 PDX MODELS MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing demand for personalized medicine
      • 5.2.1.2 Continuous support for cancer research from the public & private sectors
      • 5.2.1.3 Rising pharma R&D
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of personalized PDX models
      • 5.2.2.2 Stringent guidelines for the use of animal models in cancer research
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising demand for humanized PDX models
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Limitations of PDX models
  • 5.3 IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE PDX MODELS MARKET
  • 5.4 TECHNOLOGICAL ANALYSIS
  • 5.5 PRICING ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 19 VALUE CHAIN ANALYSIS OF PDX MODELS MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
    • FIGURE 20 VALUE CHAIN: CREATION OF PDX MODELS-MAXIMUM VALUE IS ADDED DURING THE IMPLANTATIONS OF TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS
  • 5.7 ECOSYSTEM ANALYSIS OF THE PDX MODELS MARKET
    • FIGURE 21 ECOSYSTEM ANALYSIS OF THE PDX MODELS MARKET
    • TABLE 2 SUPPLY CHAIN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 3 PDX MODELS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 NORTH AMERICA
    • 5.9.2 EUROPE
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 China
      • 5.9.3.2 Japan
      • 5.9.3.3 India
      • 5.9.3.4 Australia
    • 5.9.4 LATIN AMERICA
    • 5.9.5 MIDDLE EAST & AFRICA
  • 5.10 PATENT ANALYSIS
    • FIGURE 22 PATENTS GRANTED FOR PDX MODELS, JANUARY 2010-DECEMBER 2020

6 PDX MODELS MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 4 PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
  • 6.2 MICE MODELS
    • 6.2.1 EASE OF PROCUREMENT AND WIDE AVAILABILITY OF MICE MODELS DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 5 PDX MICE MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 6 NORTH AMERICA: PDX MICE MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 7 EUROPE: PDX MICE MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 8 ASIA PACIFIC: PDX MICE MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.3 RAT MODELS
    • 6.3.1 FACTORS SUCH AS EASIER SURGICAL MANIPULATION AND LARGER TUMOR SIZE WILL SUPPORT USE OF RAT MODELS
    • TABLE 9 PDX RAT MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 10 NORTH AMERICA: PDX RAT MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 11 EUROPE: PDX RAT MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 12 ASIA PACIFIC: PDX RAT MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

7 PDX MODELS MARKET, BY TUMOR TYPE

  • 7.1 INTRODUCTION
    • TABLE 13 PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
  • 7.2 GASTROINTESTINAL TUMOR MODELS
    • 7.2.1 NEWLY DEVELOPED GASTROINTESTINAL TUMOR MODELS MIMIC THE TUMOR BETTER THAN PREVIOUS MODELS
    • TABLE 14 GASTROINTESTINAL TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 15 NORTH AMERICA: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 16 EUROPE: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 17 ASIA PACIFIC: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.3 GYNECOLOGICAL TUMOR MODELS
    • 7.3.1 HIGH INCIDENCE OF TARGET CANCERS HAS DRIVEN DEMAND FOR TUMOR MODELS
    • TABLE 18 GYNECOLOGICAL TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 19 NORTH AMERICA: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 20 EUROPE: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 21 ASIA PACIFIC: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.4 RESPIRATORY TUMOR MODELS
    • 7.4.1 RISING PREVALENCE OF LUNG CANCER TO DRIVE MARKET GROWTH
    • TABLE 22 RESPIRATORY TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 23 NORTH AMERICA: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 24 EUROPE: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 25 ASIA PACIFIC: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.5 UROLOGICAL TUMOR MODELS
    • 7.5.1 COMPANIES ARE FOCUSING ON EXPANDING THEIR PORTFOLIO FOR UROLOGICAL CANCERS
    • TABLE 26 UROLOGICAL TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 27 NORTH AMERICA: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 28 EUROPE: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 29 ASIA PACIFIC: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.6 HEMATOLOGICAL TUMOR MODELS
    • 7.6.1 NEW STRAINS SUCH AS NSG AND NOG HAVE INCREASED THE LIFE SPAN OF HEMATOLOGICAL TUMOR MODELS
    • TABLE 30 HEMATOLOGICAL TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 31 NORTH AMERICA: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 32 EUROPE: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 33 ASIA PACIFIC: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.7 OTHER TUMOR MODELS
    • TABLE 34 OTHER TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 35 NORTH AMERICA: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 36 EUROPE: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

8 PDX MODELS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 38 PDX MODELS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
  • 8.2 PRECLINICAL DRUG DEVELOPMENT
    • 8.2.1 RISE IN NUMBER OF CLINICAL TRIALS WILL DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 39 PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 40 NORTH AMERICA: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 41 EUROPE: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.3 BIOMARKER ANALYSIS
    • 8.3.1 GROWING INTEREST IN PRECISION MEDICINE WILL CONTRIBUTE TO THE DEMAND FOR PDX MODELS FOR BIOMARKER ANALYSIS
    • TABLE 43 PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 44 NORTH AMERICA: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 45 EUROPE: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 46 ASIA PACIFIC: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.4 BASIC CANCER RESEARCH
    • 8.4.1 RISING FUNDING FOR CANCER RESEARCH WILL DRIVE MARKET GROWTH IN THIS SEGMENT
    • TABLE 47 PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 48 NORTH AMERICA: PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 49 EUROPE: PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 50 ASIA PACIFIC: PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019-2026 (USD MILLION)

9 PDX MODELS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 51 PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 RISING COLLABORATION BETWEEN PHARMA & BIOTECH COMPANIES FOR DEVELOPING CANCER THERAPEUTICS
    • TABLE 52 PDX MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 53 NORTH AMERICA: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 54 EUROPE: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.3 CONTRACT RESEARCH ORGANIZATIONS
    • 9.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES WILL DRIVE MARKET GROWTH
    • TABLE 56 PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 57 NORTH AMERICA: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 58 EUROPE: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.4 ACADEMIC & RESEARCH INSTITUTIONS
    • 9.4.1 INCREASE IN GOVERNMENT LIFE SCIENCES R&D EXPENDITURE WILL CONTRIBUTE TO THE GROWTH OF THIS SEGMENT
    • TABLE 60 PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 61 NORTH AMERICA: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 62 EUROPE: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019-2026 (USD MILLION)

10 PDX MODELS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 64 PDX MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 23 NORTH AMERICA: PDX MODELS MARKET SNAPSHOT
    • TABLE 65 NORTH AMERICA: PDX MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 66 NORTH AMERICA: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 67 NORTH AMERICA: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 68 NORTH AMERICA: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 69 NORTH AMERICA: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Growing focus on cancer research in the US will drive market growth
    • TABLE 70 US: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 71 US: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 72 US: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 73 US: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Growth in Canada can be attributed to rising funding for stem cell research in the country
    • TABLE 74 CANADA: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 75 CANADA: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 76 CANADA: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 77 CANADA: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 78 EUROPE: PDX MODELS MARKET, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
    • TABLE 79 EUROPE: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 80 EUROPE: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 81 EUROPE: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 82 EUROPE: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Government funding for life science R&D and basic cancer research will drive market growth
    • TABLE 83 GERMANY: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 84 GERMANY: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 85 GERMANY: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 86 GERMANY: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth
    • TABLE 87 UK: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 88 UK: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 89 UK: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 90 UK: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing government funding for cancer research
    • TABLE 91 FRANCE: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 92 FRANCE: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 93 FRANCE: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 94 FRANCE: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.4 ROE
    • TABLE 95 ROE: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 96 ROE: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 97 ROE: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 98 ROE: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 24 ASIA PACIFIC: PDX MODELS MARKET SNAPSHOT
    • TABLE 99 ASIA PACIFIC: PDX MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 101 ASIA PACIFIC: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 102 ASIA PACIFIC: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 103 ASIA PACIFIC: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 The growing pharmaceutical industry and rising number of CROs in the country will drive market growth
    • TABLE 104 CHINA: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 105 CHINA: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 106 CHINA: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 107 CHINA: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Research collaborations and growing geriatric population-key growth drivers in Japan
    • TABLE 108 JAPAN: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 109 JAPAN: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 110 JAPAN: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 111 JAPAN: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.3 REST OF ASIA PACIFIC
    • TABLE 112 ROAPAC: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 113 ROAPAC: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 114 ROAPAC: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 115 ROAPAC: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET
    • TABLE 116 LATIN AMERICA: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 117 LATIN AMERICA: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 118 LATIN AMERICA: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 119 LATIN AMERICA: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D
    • TABLE 120 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 121 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 122 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 123 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 MARKET EVALUATION FRAMEWORK
    • TABLE 124 MARKET EVALUATION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, JOINT VENTURES, AND COLLABORATIONS-THE MAJOR STRATEGIES ADOPTED BY PLAYERS
  • 11.3 MARKET SHARE ANALYSIS
    • FIGURE 25 PDX MODELS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
  • 11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 26 TOP MARKET PLAYERS DOMINATE THE PDX MODELS MARKET
  • 11.5 COMPANY EVALUATION QUADRANT
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE
    • 11.5.4 EMERGING COMPANIES
    • FIGURE 27 PDX MODELS MARKET: COMPANY EVALUATION QUADRANT, 2020
  • 11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 28 PDX MODELS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
  • 11.7 COMPANY PRODUCT FOOTPRINT
    • TABLE 125 PRODUCT PORTFOLIO ANALYSIS: PDX MODELS MARKET (2020)
  • 11.8 COMPANY GEOGRAPHIC FOOTPRINT
    • TABLE 126 GEOGRAPHIC REVENUE MIX: PDX MODELS MARKET (2020)
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PDX MODELS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2018-FEBRUARY 2021
    • 11.9.2 PDX MODELS MARKET: DEALS, JANUARY 2019-FEBRUARY 2021
    • 11.9.3 PDX MODELS MARKET: OTHER DEVELOPMENTS, JANUARY 2018-FEBRUARY 2021

12 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)**
  • 12.1 KEY MARKET PLAYERS
    • 12.1.1 JSR CORPORATION
    • FIGURE 29 JSR CORPORATION: COMPANY SNAPSHOT (2019)
    • 12.1.2 WUXI APPTEC
    • FIGURE 30 WUXI APPTEC: COMPANY SNAPSHOT (2020)
    • 12.1.3 THE JACKSON LABORATORY
    • FIGURE 31 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2019)
    • 12.1.4 CHARLES RIVER LABORATORIES
    • FIGURE 32 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)
    • 12.1.5 CHAMPIONS ONCOLOGY
    • FIGURE 33 CHAMPIONS ONCOLOGY: COMPANY SNAPSHOT (2020)
    • 12.1.6 ONCODESIGN
    • FIGURE 34 ONCODESIGN: COMPANY SNAPSHOT (2020)
    • 12.1.7 ENVIGO
    • 12.1.8 PHARMATEST SERVICES
    • 12.1.9 HERA BIOLABS
    • 12.1.10 EPO BERLIN-BUCH GMBH
    • 12.1.11 XENTECH
    • 12.1.12 UROSPHERE
  • 12.2 OTHER PLAYERS
    • 12.2.1 ABNOVA CORPORATION
    • 12.2.2 GENESIS BIOTECHNOLOGY GROUP
    • 12.2.3 EXPLORA BIOLABS
    • 12.2.4 BIOCYTOGEN
    • 12.2.5 LIVING TUMOR LABORATORY
    • 12.2.6 BIODURO
    • 12.2.7 ARAGEN LIFE SCIENCES W.E.F
    • 12.2.8 SHANGHAI LIDE BIOTECH
  • *Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
Back to Top
전화 문의
F A Q